In a world where diseases spread globally within days, relying on closed, proprietary technologies is dangerously outdated. At Varro, we're revolutionizing disease prevention through open hardware innovation.

Our platform centers on the micro immuno-electrode (MIE), a breakthrough technology combining hardware engineering with pathogen detection. While traditional biotech companies build patent walls, we're making our designs, specifications, and manufacturing processes openly available. This enables local production and adaptation of life-saving devices worldwide.

The COVID-19 pandemic exposed how proprietary approaches delay protection for vulnerable communities. Our open hardware model changes this by enabling rapid local deployment. We maintain competitive advantage through manufacturing excellence and R&D innovation, not restriction. We're building a state-of-the-art facility to produce high-quality, affordable MIEs while developing a comprehensive nanobody library for rapid response to emerging threats.

Key takeaways: • Open hardware enables local manufacturing of pathogen detection technology • Innovation comes from engineering excellence, not patent restrictions • Global protection requires distributed production and adaptation

The future of disease prevention isn't in patents and restrictions—it's in open access and global collaboration. Together, we can build a world better prepared to protect itself from infectious diseases.